Skip to main content
We will be working on site updates on Wednesday, July 26. The platform should operate normally for most of the day, except for a 2-4 hour long disruption during maintenance. We apologize for any inconvenience.
3.148.112.132

The Evolving State of Continuous Processing in Pharmaceutical API Manufacturing: A Survey of Pharmaceutical Companies and Contract Manufacturing Organizations

By McWilliams, JC; Allian, ADOpalka, SM; May, SA; Journet, M; Braden, TM

Published on CMKC

Abstract

This manuscript provides the results of an in-depth survey assessment of the capabilities, experience, and perspectives on continuous processing in the pharmaceutical sector, with respondents from both pharmaceutical companies and Contract Manufacturing Organizations (CMOs). The survey includes staffing (personnel), chemistry, reaction platforms, postreaction processing, analytical, regulatory, and factors that influence the adoption of continuous manufacturing. The results of the survey demonstrate that the industry has been increasing, and will continue to increase, the portion of total manufacturing executed as continuous processes with a decrease in batch processing. In general, most of the experience with continuous processing on scale have been enabling reaction chemistry, while postprocessing and analytical remain in the very early stages of development and implementation.

Journal

Organic Process Research & Development. Volume 22, 2018, 1143-1166

DOI

10.1021/acs.oprd.8b00160

Type of publication

Peer-reviewed journal

Affiliations

  • Pfizer Worldwide Research & Development
  • Amgen Inc
  • Eli Lilly & Co; Biogen Idec Inc; GlaxoSmithKline

Article Classification

Research Article

Classification Areas

  • API

Tags